

## Matthew Grumbling

Senior Counsel

[mgrumbling@youngbasile.com](mailto:mgrumbling@youngbasile.com)

3001 West Big Beaver Rd., Suite 624  
Troy, MI 48084

P: 248-244-0137

F: 248-649-3338

### Practice Areas

Patent  
Litigation

### Industries

Chemical & Materials  
Medical Devices

### Education

George Washington University  
School of Law, J.D.  
  
Johns Hopkins University,  
M.A., Chemistry  
  
University of Arizona  
B.S., Chemistry

### Admissions

U.S. Patent and Trademark Office  
U.S. District Court, District of  
Arizona  
U.S. Supreme Court  
State of Arizona  
State of Maryland  
State of California

Mr. Grumbling is a highly experienced patent attorney focusing on pharmaceutical and life sciences, with over 20 years' experience in all aspects of IP counselling, including preparation and prosecution, IP diligence and risk management, freedom-to-operate analyses, patent opinions, infringement complaints, and negotiating and drafting IP licenses and settlement agreements.

Mr. Grumbling's first exposure to patent work was at the United States Patent and Trademark Office (USPTO), where he applied his chemical expertise to as a patent examiner, attaining the level of primary examiner, in the art of small molecule heterocyclic chemistry.

### Industry Experience

Mr. Grumbling's experience in the private sector includes advising clients in various stages of development, from startups and universities to large public companies. His technical expertise spans pharmaceuticals, from small molecules to antibodies and ADCs, in diverse therapeutic sectors, such as women's health, neurology, seizure and gastroparesis therapies, cardiovascular, antiviral and cancer therapeutics. His legal experience includes patent drafting and acquisition, licensing, and worldwide patent procurement and prosecution strategy.

Mr. Grumbling has a proven track record, having assisted his clients in securing essential IP rights that significantly contributed to successful multi-million dollar deals for his clients. Notable deals include public stock placement, as well as mergers and acquisitions ranging in value from over \$10 million to \$1.3 billion for clients in injectable pharmaceuticals, transdermal drug-delivery devices, artificial skin prosthetics, Alzheimer's and Parkinson's therapeutics, and cancer chemotherapy.